Hope for ME/CFS and long COVID: new drug combo trial launches

NCT ID NCT06366724

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs—pyridostigmine (Mestinon) and low-dose naltrexone (LDN)—alone or together in 160 adults with ME/CFS or Long COVID who also have orthostatic intolerance (difficulty standing). Over 3 months, participants take gradually increasing doses and complete exercise tests and questionnaires to see if the drugs improve daily function and energy. The goal is to find better treatment options for these debilitating conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN)
What this could lead to: If successful, this could point toward a new treatment combination to improve daily function and energy in people with ME/CFS and Long COVID.
What could go wrong: This is a mid-stage trial with only 160 participants, so results may not apply to everyone. Side effects from the medications could limit tolerability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome Orthostatic Intolerance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID ME/CFS PASC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.